Tech Company Financing Transactions
Primmune Therapeutics Funding Round
Primmune Therapeutics, operating out of San Diego, raised $7 million from Biobrit, BioRock Ventures and CAM Capital.
Transaction Overview
Company Name
Announced On
3/3/2020
Transaction Type
Venture Equity
Amount
$7,000,000
Round
Seed
Investors
Proceeds Purpose
Primmune Therapeutics will use financing to Develop Novel Oral TLR7 Immunotherapies for Cancer and Acute Viral Diseases
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3210 Merryfield Row
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Undisclosed
Website
Email Address
Overview
Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Charles McDermott
Vice President
Stephen Webber
VP - Bus. Development
Paulo Rangel
VP - R & D
James Appleman
Browse more venture capital transactions:
Prev: 3/3/2020: BucksApp venture capital transaction
Next: 3/3/2020: Run The World venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC transactions on this site are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs